References
- Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis 2013;34:2145–2155.
- Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer 2008;15:721–743.
- Kakar SS, Malik MT. Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol 2006;29:387–395.
- Tong Y, Eigler T. Transcriptional targets for pituitary tumor-transforming gene-1. J Mol Endocrinol 2009;43:179–185.
- Sánchez-Puig N, Veprintsev DB, Fersht AR. Human full-length Securin is a natively unfolded protein. Protein Sci 2005;14:1410–1418.
- Boelaert K, Yu R, Tannahill LA, Stratford AL, Khanim FL, Eggo MC, et al. PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. J Mol Endocrinol 2004;33:663–677.
- Saksela K, Permi P. SH3 domain ligand binding: What's the consensus and where's the specificity? FEBS Lett 2012;586:2609–2614.
- Domínguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, et al. hPTTG, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 1998;17:2187–2193.
- Kärkkäinen S, Hiipakka M, Wang JH, Kleino I, Vähä-Jaakkola M, Renkema GH, et al. Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome. EMBO Rep 2006;7:186–191.
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235–242.
- Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res 2014;42:W252–W258.
- Mayer BJ. SH3 domains: complexity in moderation. J Cell Sci 2001;114:1253–1263.
- Adzhubei AA, Sternberg MJ, Makarov AA. Polyproline-II helix in proteins: structure and function. J Mol Biol 2013;425:2100–2132.
- Song Y, Tyka M, Leaver-Fay A, Thompson J, Baker D. Structure-guided forcefield optimization. Proteins 2011;79:1898–1909.
- Sammond DW, Eletr ZM, Purbeck C, Kimple RJ, Siderovski DP, Kuhlman B. Structure-based protocol for identifying mutations that enhance protein-protein binding affinities. J Mol Biol 2007;371:1392–1404.
- Combs SA, Deluca SL, Deluca SH, Lemmon GH, Nannemann DP, Nguyen ED, et al. Small-molecule ligand docking into comparative models with Rosetta. Nat Protoc 2013;8:1277–1298.
- Schumacher C, Knudsen BS, Ohuchi T, Di Fiore PP, Glassman RH, Hanafusa H. The SH3 domain of Crk binds specifically to a conserved proline-rich motif in Eps15 and Eps15R. J Biol Chem 1995;270:15341–15347.
- van de Weerdt BC, Littler DR, Klompmaker R, Huseinovic A, Fish A, Perrakis A, et al. Polo-box domains confer target specificity to the Polo-like kinase family. Biochim Biophys Acta 2008;1783:1015–1022.
- van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem 2005;26:1701–1718.
- Xu XL, Wang X, Chen ZL, Jin M, Yang W, Zhao GF, et al. Overexpression of Grb2-associated binder 2 in human lung cancer. Int J Biol Sci 2011;7:496–504.
- Sastry L, Cao T, King CR. Multiple Grb2-protein complexes in human cancer cells. Int J Cancer 1997;70:208–213.
- Pezeshkpour GH, Moatamed F, Lewis M, Hoang B, Rettig M, Mortazavi F. CRK SH3N domain diminishes cell invasiveness of non-small cell lung cancer. Genes Cancer 2013;4:315–324.
- Shim JH, Su ZY, Chae JI, Kim DJ, Zhu F, Ma WY, et al. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev Res 2010;3:670–679.
- Birge RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal 2009;7:13.